Avant Immunotherapeutics, Inc.
Records under this name other than patents Avant Immunotherapeutics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Avant Immunotherapeutics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,841,373 | Herpes virus complementing cell line Formerly held Term ended Term ended Apr 22, 2021 · USPTO record | Term ended | Term ended Apr 22, 2021 | USPTO record |
| US 8,287,855 | V. cholerae hyperexpressing recombinant cholera toxin B subunit showing dual immunogenicity Formerly held Lapsed on the fee record Ended Oct 16, 2020 · USPTO record | Lapsed on the fee record | Ended Oct 16, 2020 | USPTO record |
| US 6,780,405 | Regulated antigen delivery system (RADS) Formerly held Term ended Term ended Apr 28, 2020 · USPTO record | Term ended | Term ended Apr 28, 2020 | USPTO record |
| US 7,341,860 | Regulated Antigen Delivery System (RADS) Formerly held Lapsed on the fee record Ended Mar 11, 2020 · Medium confidence | Lapsed on the fee record | Ended Mar 11, 2020 | Medium confidence |
| US 6,261,573 | Immunoadjuvants Term ended Term ended Oct 25, 2019 · USPTO record | Term ended | Term ended Oct 25, 2019 | USPTO record |
| US 7,871,604 | Recombinant bacterial vaccine system with environmentally limited viability Formerly held Lapsed on the fee record Ended Jan 18, 2019 · USPTO record | Lapsed on the fee record | Ended Jan 18, 2019 | USPTO record |
| US 6,316,604 | Human C3b/C4b receptor (CR1) Formerly held Term ended Term ended Nov 13, 2018 · USPTO record | Term ended | Term ended Nov 13, 2018 | USPTO record |
| US 6,015,563 | Polyphosphazene polyelectrolyte immunoadjuvants Term ended Term ended Nov 4, 2018 · USPTO record | Term ended | Term ended Nov 4, 2018 | USPTO record |
| US 6,610,529 | Recombinant bacterial system with environmentally limited viability Formerly held Term ended Term ended Jun 7, 2015 · USPTO record | Term ended | Term ended Jun 7, 2015 | USPTO record |
| US 6,479,284 | Humanized antibody and uses thereof Formerly held Lapsed on the fee record Ended Nov 12, 2014 · USPTO record | Lapsed on the fee record | Ended Nov 12, 2014 | USPTO record |